Published on 2 Feb 2022 on Simply Wall St. via Yahoo Finance

When Will Pulmatrix, Inc. (NASDAQ:PULM) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Pulmatrix, Inc.'s (NASDAQ:PULM) future prospects. Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. With the latest financial year loss of US$19m and a trailing-twelve-month loss of US$19m, the US$23m market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Pulmatrix will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Check out our latest analysis for Pulmatrix

Expectations from some of the American Pharmaceuticals analysts is that Pulmatrix is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$20m in 2024. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2024? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.